CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | antiamoebic agent |
|
Accession: | CHEBI:171664
|
browse the term
|
Definition: | An antiparasitic agent which is effective against amoeba, a genus of single-celled amoeboids in the family Amoebidae. |
Synonyms: | related_synonym: | amebicide; amebicides; amoebicide; amoebicides; anti-amoebic agent; anti-amoebic agents; anti-amoebic drug; anti-amoebic drugs; antiamoebic; antiamoebic agents; antiamoebic drug; antiamoebic drugs; antiamoebics |
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ABCA12 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:80,272,121...80,445,340
Ensembl chr 9:72,823,350...72,996,049
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB11 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB1A mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC3 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ABCG1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Acrv1 |
acrosomal vesicle protein 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ACRV1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:44,593,246...44,598,823
Ensembl chr 8:36,404,394...36,424,959
|
|
G |
Adamts12 |
ADAM metallopeptidase with thrombospondin type 1 motif, 12 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ADAMTS12 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:60,032,873...60,327,629
Ensembl chr 2:60,032,873...60,327,629
|
|
G |
Adcy2 |
adenylate cyclase 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ADCY2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:36,204,054...36,650,645
Ensembl chr 1:34,375,895...34,822,236
|
|
G |
Adora3 |
adenosine A3 receptor |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ADORA3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ADRA2A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Aldh8a1 |
aldehyde dehydrogenase 8 family, member A1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ALDH8A1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:16,183,940...16,203,385
Ensembl chr 1:16,183,940...16,203,385
|
|
G |
Alk |
ALK receptor tyrosine kinase |
increases expression |
ISO |
Amphotericin B results in increased expression of ALK mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:28,631,431...29,351,321
Ensembl chr 6:22,880,625...23,598,034
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ALOX5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Amacr |
alpha-methylacyl-CoA racemase |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of AMACR mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:61,673,291...61,685,381
Ensembl chr 2:59,946,153...59,958,255
|
|
G |
Ank3 |
ankyrin 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ANK3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:18,601,307...19,224,790
Ensembl chr20:18,602,786...19,086,300
|
|
G |
Anxa9 |
annexin A9 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ANXA9 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374
|
|
G |
Ap3b2 |
adaptor related protein complex 3 subunit beta 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of AP3B2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:144,821,819...144,854,533
Ensembl chr 1:135,412,580...135,445,191
|
|
G |
Apbb2 |
amyloid beta precursor protein binding family B member 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of APBB2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:41,557,918...41,878,622
Ensembl chr14:41,557,972...41,877,495
|
|
G |
Apoc2 |
apolipoprotein C2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of APOC2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:88,457,397...88,462,365
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of AQP3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp5 |
aquaporin 5 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of AQP5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Arg2 |
arginase 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ARG2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
ISO |
Amphotericin B results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:146,740,336...146,850,918
Ensembl chr 2:146,739,631...146,850,819
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer] |
CTD |
PMID:16189267 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arrb1 |
arrestin, beta 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ARRB1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Atg3 |
autophagy related 3 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:69,130,948...69,159,280
Ensembl chr11:55,624,917...55,653,224
|
|
G |
Atp10b |
ATPase phospholipid transporting 10B |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ATP10B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:27,495,207...27,751,313
Ensembl chr10:27,408,747...27,749,637
|
|
G |
B3gnt4 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of B3GNT4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr12:33,070,221...33,073,904
Ensembl chr12:33,060,416...33,073,854
|
|
G |
Bag4 |
BAG cochaperone 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of BAG4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr16:72,991,407...73,008,620
Ensembl chr16:66,288,678...66,308,663
|
|
G |
Bcl6 |
BCL6, transcription repressor |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of BCL6 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:90,358,753...90,382,049
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bend5 |
BEN domain containing 5 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of BEND5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:131,519,214...131,565,228
Ensembl chr 5:125,254,956...126,534,367
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of BMP2 mRNA; Amphotericin B results in decreased expression of BMP2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of BMP7 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bnc1 |
basonuclin zinc finger protein 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of BNC1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:145,326,881...145,352,534
Ensembl chr 1:135,917,687...135,943,333
|
|
G |
Bora |
bora, aurora kinase A activator |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of BORA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CAMK2G mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:3,553,238...3,612,310
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Capn6 |
calpain 6 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CAPN6 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:112,177,467...112,202,178
Ensembl chr X:107,380,774...107,405,489
|
|
G |
Car12 |
carbonic anhydrase 12 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CA12 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car14 |
carbonic anhydrase 14 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CA14 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:186,131,196...186,138,164
Ensembl chr 2:183,441,667...183,449,693
|
|
G |
Car4 |
carbonic anhydrase 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CA4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:70,325,102...70,333,916
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Car9 |
carbonic anhydrase 9 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CA9 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:62,559,024...62,565,626
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Carf |
calcium responsive transcription factor |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CARF mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:68,996,419...69,046,480
Ensembl chr 9:61,506,956...61,550,462
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
Amphotericin B results in increased expression of CASP3 protein |
CTD |
PMID:23988732 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casq2 |
calsequestrin 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CASQ2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:192,214,556...192,270,821
Ensembl chr 2:189,525,960...189,582,267
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Amphotericin B results in decreased expression of CAT mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CCL20 mRNA; Amphotericin B results in increased expression of CCL20 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of CCNE2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of CCR2 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CD14 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd1d1 |
CD1d1 molecule |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CD1D mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:174,721,522...174,725,029
Ensembl chr 2:172,423,582...172,427,089
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CD2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:191,399,510...191,412,659
Ensembl chr 2:188,710,900...188,724,026
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CD3E mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd84 |
CD84 molecule |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CD84 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:86,859,979...86,899,984
Ensembl chr13:84,327,553...84,362,076
|
|
G |
Cdkl5 |
cyclin-dependent kinase-like 5 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CDKL5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:33,757,605...33,988,075
Ensembl chr X:33,821,257...33,986,582
|
|
G |
Cdsn |
corneodesmosin |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CDSN mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:3,179,432...3,184,252
Ensembl chr20:3,179,438...3,184,250
|
|
G |
Ceacam15 |
CEA cell adhesion molecule 15 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CEACAM21 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:77,368,376...77,373,343
Ensembl chr 1:77,368,966...77,372,663
|
|
G |
Cep76 |
centrosomal protein 76 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CEP76 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr18:63,444,389...63,478,358
Ensembl chr18:61,178,310...61,208,504
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CGA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CHAC1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:48,193,839...48,201,822
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chl1 |
cell adhesion molecule L1-like |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CHL1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:137,847,648...138,062,077
Ensembl chr 4:136,291,463...136,503,265
|
|
G |
Chp1 |
calcineurin-like EF-hand protein 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CHP1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:106,536,004...106,571,251
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CHRNB3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr16:71,411,847...71,454,225
Ensembl chr16:64,714,169...64,751,360
|
|
G |
Clu |
clusterin |
affects expression decreases expression |
EXP ISO |
Amphotericin B affects the expression of CLU mRNA Amphotericin B analog results in decreased expression of CLU mRNA |
CTD |
PMID:20623750 PMID:28534445 |
|
NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cmah |
cytidine monophospho-N-acetylneuraminic acid hydroxylase |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CMAHP mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:40,985,129...41,070,317
Ensembl chr17:40,583,667...40,642,275
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CNR2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cntn5 |
contactin 5 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CNTN5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:6,735,715...7,967,727
Ensembl chr 8:6,738,239...7,967,957
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
increases expression |
ISO |
Amphotericin B analog results in increased expression of COL5A1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Amphotericin B analog results in increased expression of COMT mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cpd |
carboxypeptidase D |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CPD mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:61,623,528...61,687,491
Ensembl chr10:61,623,526...61,687,491
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CPT1B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:122,370,974...122,380,473
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CRISPLD2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465
|
|
G |
Crybb1 |
crystallin, beta B1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CRYBB1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr12:44,369,734...44,383,344
Ensembl chr12:44,369,735...44,383,344
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CSF2 mRNA; Amphotericin B results in increased expression of CSF2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csgalnact2 |
chondroitin sulfate N-acetylgalactosaminyltransferase 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CSGALNACT2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:152,944,154...152,981,237
Ensembl chr 4:151,277,645...151,308,839
|
|
G |
Cspg5 |
chondroitin sulfate proteoglycan 5 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CSPG5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CXCL1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CXCL2 mRNA; Amphotericin B results in increased expression of CXCL2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CXCL1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CXCR4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CYP2C19 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of CYP4B1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Cyth4 |
cytohesin 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of CYTH4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:110,152,232...110,176,726
Ensembl chr 7:110,152,272...110,176,741
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of DCLK1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
increases expression |
ISO |
Amphotericin B analog results in increased expression of DCSTAMP mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:72,692,364...72,706,983
Ensembl chr 7:70,807,581...70,822,078
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Amphotericin B results in increased expression of DDIT3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx11 |
DEAD/H-box helicase 11 |
increases expression |
ISO |
Amphotericin B results in increased expression of DDX11 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:113,204,886...113,309,692
Ensembl chr 9:105,833,504...105,862,550
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of DEPTOR mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dhrs7 |
dehydrogenase/reductase 7 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of DHRS7 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892
|
|
G |
Dicer1 |
dicer 1 ribonuclease III |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of DICER1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:129,392,298...129,457,252
Ensembl chr 6:123,631,250...123,693,965
|
|
G |
Dkk4 |
dickkopf WNT signaling pathway inhibitor 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of DKK4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr16:76,105,679...76,109,044
Ensembl chr16:69,402,989...69,406,580
|
|
G |
Dlgap1 |
DLG associated protein 1 |
decreases expression increases expression |
ISO |
Amphotericin B analog results in decreased expression of DLGAP1 mRNA Amphotericin B analog results in increased expression of DLGAP1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:117,304,144...118,173,463
Ensembl chr 9:110,167,448...110,726,817
|
|
G |
Dnah3 |
dynein, axonemal, heavy chain 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of DNAH3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:183,738,013...183,910,831
Ensembl chr 1:174,306,644...174,479,474
|
|
G |
Dnaja4 |
DnaJ heat shock protein family (Hsp40) member A4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of DNAJA4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:55,085,246...55,102,715
Ensembl chr 8:55,085,464...55,101,207
|
|
G |
Dtx4 |
deltex E3 ubiquitin ligase 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of DTX4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:218,882,391...218,969,837
Ensembl chr 1:209,460,735...209,492,818
|
|
G |
Duox2 |
dual oxidase 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of DUOX2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:129,680,543...129,698,886
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Dzip3 |
DAZ interacting zinc finger protein 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of DZIP3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:65,286,190...65,356,314
Ensembl chr11:51,823,231...51,893,353
|
|
G |
E2f2 |
E2F transcription factor 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of E2F2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Amphotericin B results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Efr3b |
EFR3 homolog B |
increases expression |
ISO |
Amphotericin B analog results in increased expression of EFR3B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:32,664,593...32,740,417
Ensembl chr 6:26,948,540...27,020,933
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of EGLN3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:77,385,549...77,411,015
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of EMX2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
Eno1 |
enolase 1 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of ENO1 mRNA]; Amphotericin B results in increased expression of and results in increased secretion of ENO1 protein |
CTD |
PMID:16189267 PMID:26259607 |
|
NCBI chr 5:166,002,867...166,014,252
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ENPP2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:16189267 |
|
NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epo |
erythropoietin |
multiple interactions decreases expression |
ISO EXP |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] Amphotericin B results in decreased expression of EPO protein |
CTD |
PMID:697352 PMID:2299214 PMID:16189267 |
|
NCBI chr12:24,841,285...24,844,725
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epor |
erythropoietin receptor |
increases expression |
ISO |
Amphotericin B analog results in increased expression of EPOR mRNA; Amphotericin B results in increased expression of EPOR mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:28,765,738...28,770,371
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Amphotericin B analog results in increased expression of EREG mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Fam13a |
family with sequence similarity 13, member A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FAM13A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:88,056,521...88,155,782
Ensembl chr 4:88,058,403...88,155,860
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA |
CTD |
PMID:36464106 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of FBLN1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fcgr1a |
Fc gamma receptor 1A |
increases expression |
ISO |
Amphotericin B analog results in increased expression of FCGR1A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:186,539,941...186,548,941
Ensembl chr 2:183,851,077...183,859,994
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FGB mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf4 |
fibroblast growth factor 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of FGF4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:209,453,229...209,457,085
Ensembl chr 1:200,024,056...200,025,466
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FKBP5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FLRT3 mRNA; Amphotericin B results in decreased expression of FLRT3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Amphotericin B analog results in increased expression of FOSB mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Frmd4b |
FERM domain containing 4B |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FRMD4B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:129,895,401...130,222,070
Ensembl chr 4:129,895,708...130,084,197
|
|
G |
Fsbp |
fibrinogen silencer binding protein |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FSBP mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:25,058,003...25,064,276
Ensembl chr 5:25,032,066...25,104,616
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FUBP1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:243,819,529...243,846,544
Ensembl chr 2:241,159,512...241,186,602
|
|
G |
Fxr1 |
FMR1 autosomal homolog 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FXR1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:118,812,287...118,865,813
Ensembl chr 2:116,884,248...116,937,590
|
|
G |
Fxyd3 |
FXYD domain-containing ion transport regulator 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of FXYD3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:95,432,918...95,440,129
|
|
G |
Gal3st1 |
galactose-3-O-sulfotransferase 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of GAL3ST1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388
|
|
G |
Galr3 |
galanin receptor 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GALR3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:112,483,183...112,496,359
Ensembl chr 7:110,605,226...110,607,685
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GDF15 mRNA; Amphotericin B results in increased expression of GDF15 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GFRA3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr18:26,571,952...26,600,225
Ensembl chr18:26,297,829...26,326,105
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GFRA4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:138,707,970...138,715,279
Ensembl chr 3:118,255,402...118,258,329
|
|
G |
Glce |
glucuronic acid epimerase |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of GLCE mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:71,441,607...71,507,639
Ensembl chr 8:62,546,107...62,612,040
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:61,575,770...61,594,111
Ensembl chr10:61,066,421...61,095,898
|
|
G |
Gls |
glutaminase |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GLS mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of GLUL mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gp1ba |
glycoprotein Ib platelet subunit alpha |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GP1BA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:55,831,901...55,856,729
Ensembl chr10:55,352,899...55,356,774
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
increases expression |
ISO |
Amphotericin B results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 7:105,601,761...105,611,959
Ensembl chr 7:105,602,368...105,603,430
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein |
CTD |
PMID:36464106 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grid2 |
glutamate ionotropic receptor delta type subunit 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GRID2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:92,415,019...93,892,472
Ensembl chr 4:92,415,230...93,889,355
|
|
G |
Grm6 |
glutamate metabotropic receptor 6 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of GRM6 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:35,669,003...35,683,729
Ensembl chr10:35,167,985...35,182,717
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression multiple interactions |
EXP ISO |
Amphotericin B results in decreased expression of GSTP1 mRNA Amphotericin B inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:20623750 PMID:23769903 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of GSTT1 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,669...12,873,585
|
|
G |
H2ac4 |
H2A clustered histone 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HIST1H2AC mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:47,495,624...47,496,127
Ensembl chr17:42,799,652...42,800,381
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases activity |
ISO |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]]; Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] Amphotericin B results in decreased activity of HIF1A protein |
CTD |
PMID:16189267 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hif1an |
hypoxia inducible factor 1 subunit alpha inhibitor |
multiple interactions |
ISO |
Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] |
CTD |
PMID:16189267 |
|
NCBI chr 1:243,419,175...243,440,464
Ensembl chr 1:243,419,194...243,434,327
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HILPDA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557
|
|
G |
Hipk1 |
homeodomain interacting protein kinase 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HIPK1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:193,937,261...193,988,247
Ensembl chr 2:191,248,817...191,298,902
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of HMOX1 mRNA; Amphotericin B results in increased expression of HMOX1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hook1 |
hook microtubule-tethering protein 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HOOK1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:115,940,199...116,003,482
Ensembl chr 5:110,824,501...110,887,787
|
|
G |
Hoxd3 |
homeo box D3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HOXD3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:80,041,598...80,057,700
Ensembl chr 3:59,638,708...59,650,282
|
|
G |
Hoxd4 |
homeo box D4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HOXD4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:80,021,886...80,041,462
Ensembl chr 3:59,614,464...59,631,528
|
|
G |
Hpx |
hemopexin |
increases expression |
ISO |
Amphotericin B analog results in increased expression of HPX mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HSPA1A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HSPA1B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of HSPA2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:100,864,172...100,866,946
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
Amphotericin B results in increased expression of and results in increased secretion of HSPA8 protein |
CTD |
PMID:26259607 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspb3 |
heat shock protein family B (small) member 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of HSPB3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:45,295,285...45,295,999
Ensembl chr 2:45,295,053...45,296,145
|
|
G |
Htr3a |
5-hydroxytryptamine receptor 3A |
increases expression |
ISO |
Amphotericin B analog results in increased expression of HTR3A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:58,138,514...58,150,960
Ensembl chr 8:49,242,020...49,254,389
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ICAM1 mRNA; Amphotericin B results in increased expression of ICAM1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ID2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Id4 |
inhibitor of DNA binding 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ID4 mRNA; Amphotericin B results in decreased expression of ID4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:16,595,724...16,598,293
Ensembl chr17:16,389,387...16,392,470
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Antimony Sodium Gluconate co-treated with Amphotericin B] results in increased expression of IFNG protein Amphotericin B analog results in increased expression of IFNG mRNA |
CTD |
PMID:17911647 PMID:28534445 PMID:29594315 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
increases expression |
ISO |
Amphotericin B results in increased expression of IFNGR1 |
CTD |
PMID:12803856 |
|
NCBI chr 1:16,152,811...16,171,439
Ensembl chr 1:14,333,187...14,351,785
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of IL10 protein |
CTD |
PMID:17911647 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of IL13RA2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:115,814,620...115,886,080
Ensembl chr X:111,002,592...111,072,381
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Amphotericin B results in increased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of IL1R2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il1rapl2 |
interleukin 1 receptor accessory protein-like 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of IL1RAPL2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:100,961,509...102,271,753
Ensembl chr X:100,961,812...102,271,753
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of IL6 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
Amphotericin B analog results in increased expression of INHBA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:53,787,159...53,810,942
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Ino80b |
INO80 complex subunit B |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of INO80B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:117,185,427...117,188,930
Ensembl chr 4:115,627,908...115,631,456
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of INSIG1 mRNA; Amphotericin B results in increased expression of INSIG1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Irf5 |
interferon regulatory factor 5 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of IRF5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:59,092,914...59,104,596
Ensembl chr 4:58,127,640...58,139,267
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of JAG1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Kazn |
kazrin, periplakin interacting protein |
increases expression |
ISO |
Amphotericin B analog results in increased expression of KAZN mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:154,392,793...155,381,567
Ensembl chr 5:154,392,793...154,779,074
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of KCNB1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kcnq4 |
potassium voltage-gated channel subfamily Q member 4 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:139,560,366...139,612,212
Ensembl chr 5:134,275,934...134,326,932
|
|
G |
Klf12 |
KLF transcription factor 12 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of KLF12 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:83,037,548...83,469,998
Ensembl chr15:76,637,654...77,062,056
|
|
G |
Klf9 |
KLF transcription factor 9 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of KLF9 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Klhl24 |
kelch-like family member 24 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of KLHL24 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:94,348,024...94,382,085
Ensembl chr11:80,846,755...80,877,636
|
|
G |
Klrb1a |
killer cell lectin like receptor B1A |
increases expression |
ISO |
Amphotericin B analog results in increased expression of KLRB1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:163,576,672...163,590,201
Ensembl chr 4:161,890,577...161,961,675
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of KMO mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:90,089,340...90,121,108
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Lalba |
lactalbumin, alpha |
increases expression |
ISO |
Amphotericin B analog results in increased expression of LALBA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:131,504,572...131,520,707
Ensembl chr 7:129,625,535...129,628,061
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of LCN2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Ldlrad4 |
low density lipoprotein receptor class A domain containing 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of LDLRAD4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr18:63,789,089...64,118,166
Ensembl chr18:61,521,428...61,843,238
|
|
G |
Lgals4 |
galectin 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of LGALS4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:93,248,463...93,260,002
Ensembl chr 1:84,124,764...84,132,481
|
|
G |
Limk1 |
LIM domain kinase 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of LIMK1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr12:27,663,177...27,697,085
Ensembl chr12:22,026,672...22,060,606
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lsg1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:70,132,919...70,168,526
Ensembl chr11:70,143,847...70,168,518
|
|
G |
Lyst |
lysosomal trafficking regulator |
increases expression |
ISO |
Amphotericin B analog results in increased expression of LYST mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:93,225,509...93,427,650
Ensembl chr17:86,241,384...86,443,480
|
|
G |
Madcam1 |
mucosal vascular addressin cell adhesion molecule 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MADCAM1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:10,686,920...10,690,322
Ensembl chr 7:10,036,301...10,039,703
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MAF mRNA |
CTD |
PMID:28534445 |
|
NCBI chr19:60,259,200...60,622,145
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Maoa |
monoamine oxidase A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MAOA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Amphotericin B results in increased expression of MAP1LC3B protein |
CTD |
PMID:23988732 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map3k19 |
mitogen-activated protein kinase kinase kinase 19 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MAP3K19 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:39,300,150...39,343,502
Ensembl chr13:39,300,163...39,343,767
|
|
G |
Mcm3ap |
minichromosome maintenance complex component 3 associated protein |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MCM3AP mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:12,127,570...12,165,165
Ensembl chr20:12,127,570...12,165,165
|
|
G |
Meak7 |
MTOR associated protein, eak-7 homolog |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TLDC1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr19:64,722,528...64,745,443
Ensembl chr19:47,811,416...47,841,278
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MEF2C mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:15,708,732...15,871,639
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Mir106b |
microRNA 106b |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MIR106B |
CTD |
PMID:28534445 |
|
NCBI chr12:22,157,053...22,157,134
Ensembl chr12:17,043,344...17,043,425
|
|
G |
Mir138-1 |
microRNA 138-1 |
increases expression |
ISO |
Amphotericin B results in increased expression of MIR138 |
CTD |
PMID:28534445 |
|
NCBI chr 8:131,178,434...131,178,532
Ensembl chr 8:122,300,966...122,301,064
|
|
G |
Mir17 |
microRNA 17 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MIR17 |
CTD |
PMID:28534445 |
|
NCBI chr15:98,587,848...98,587,931
Ensembl chr15:92,180,629...92,180,712
|
|
G |
Mir181c |
microRNA 181c |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MIR181C |
CTD |
PMID:28534445 |
|
NCBI chr19:40,888,291...40,888,396
Ensembl chr19:23,983,523...23,983,628
|
|
G |
Mir181d |
microRNA 181d |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MIR181D |
CTD |
PMID:28534445 |
|
NCBI chr19:23,983,706...23,983,788
Ensembl chr19:23,983,706...23,983,788
|
|
G |
Mir423 |
microRNA 423 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MIR423; Amphotericin B results in increased expression of MIR423 |
CTD |
PMID:28534445 |
|
NCBI chr10:61,914,142...61,914,220
Ensembl chr10:61,914,133...61,914,226
|
|
G |
Mir494 |
microRNA 494 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MIR494; Amphotericin B results in decreased expression of MIR494 |
CTD |
PMID:28534445 |
|
NCBI chr 6:134,550,115...134,550,197
Ensembl chr 6:128,728,709...128,728,793
|
|
G |
Mir99b |
microRNA 99b |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MIR99B |
CTD |
PMID:28534445 |
|
NCBI chr 1:58,677,015...58,677,084
Ensembl chr 1:58,677,011...58,677,090
|
|
G |
Mirlet7g |
microRNA let-7g |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MIRLET7G |
CTD |
PMID:28534445 |
|
NCBI chr 8:115,701,020...115,701,107
Ensembl chr 8:106,822,280...106,822,388
|
|
G |
Mmp28 |
matrix metallopeptidase 28 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MMP28 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:68,241,138...68,264,866
Ensembl chr10:68,241,138...68,264,866
|
|
G |
Mphosph8 |
M-phase phosphoprotein 8 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MPHOSPH8 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:30,800,546...30,828,415
Ensembl chr15:30,686,613...30,828,810
|
|
G |
Mtf2 |
metal response element binding transcription factor 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of MTF2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:1,784,218...1,828,463
Ensembl chr14:1,640,746...1,683,524
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MUC2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:206,225,775...206,261,280
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MX2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:50,375,101...50,399,373
Ensembl chr11:36,906,111...36,930,342
|
|
G |
Myo15b |
myosin XVB |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MYO15B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:101,088,734...101,126,159
Ensembl chr10:101,104,209...101,125,693
|
|
G |
Myo7a |
myosin VIIA |
increases expression |
ISO |
Amphotericin B analog results in increased expression of MYO7A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:152,342,611...152,414,171
Ensembl chr 1:152,344,448...152,414,157
|
|
G |
Nat8 |
N-acetyltransferase 8 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of NAT8 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:118,279,521...118,284,671
Ensembl chr 4:118,270,954...118,281,763
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of NEDD9 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,282,326...23,468,019
|
|
G |
Nefl |
neurofilament light chain |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of NEFL mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:46,477,330...46,481,203
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of NEFM mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:46,535,857...46,541,161
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nf2 |
NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of NF2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:83,850,894...83,934,263
Ensembl chr14:79,627,399...79,710,667
|
|
G |
Nol3 |
nucleolar protein 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of NOL3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr19:50,066,493...50,068,175
Ensembl chr19:33,154,062...33,158,250
|
|
G |
Nprl2 |
NPR2-like, GATOR1 complex subunit |
decreases expression |
ISO |
Amphotericin B results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:117,094,443...117,097,639
Ensembl chr 8:108,215,814...108,218,996
|
|
G |
Nr2e1 |
nuclear receptor subfamily 2, group E, member 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of NR2E1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:47,632,347...47,653,464
Ensembl chr20:46,050,414...46,073,949
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of NR2F1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Amphotericin B results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:255,712,797...255,838,285
Ensembl chr 1:245,772,277...245,897,913
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
decreases expression increases expression |
ISO |
Amphotericin B analog results in decreased expression of NTRK2 mRNA Amphotericin B analog results in increased expression of NTRK2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Or10j2 |
olfactory receptor family 10 subfamily J member 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of OR10J1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:88,255,644...88,256,634
Ensembl chr13:85,719,234...85,724,767
|
|
G |
Or2h2c |
olfactory receptor family 2 subfamily H member 2C |
increases expression |
ISO |
Amphotericin B analog results in increased expression of OR2H2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:1,398,964...1,399,902
Ensembl chr20:1,395,108...1,400,441
|
|
G |
Ovol2 |
ovo-like zinc finger 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of OVOL2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:152,130,767...152,160,487
Ensembl chr 3:131,677,391...131,708,359
|
|
G |
Paip1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:53,255,916...53,282,965
Ensembl chr 2:51,522,921...51,550,241
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
decreases expression |
ISO |
Amphotericin B results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:71,977,420...72,527,273
Ensembl chr19:55,080,282...55,629,778
|
|
G |
Pard6b |
par-6 family cell polarity regulator beta |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PARD6B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:156,790,540...156,811,620
Ensembl chr 3:156,790,540...156,811,622
|
|
G |
Pde1a |
phosphodiesterase 1A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PDE1A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde4d |
phosphodiesterase 4D |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PDE4D mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:41,748,337...43,262,567
Ensembl chr 2:40,019,933...41,525,884
|
|
G |
Pde4dip |
phosphodiesterase 4D interacting protein |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PDE4DIP mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379
|
|
G |
Pdlim7 |
PDZ and LIM domain 7 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PDLIM7 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:9,129,603...9,144,956
Ensembl chr17:9,124,649...9,139,811
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PECAM1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:92,090,263...92,152,002
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of PGK1 mRNA] |
CTD |
PMID:16189267 |
|
NCBI chr X:75,336,988...75,352,962
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PIK3R1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pitx2 |
paired-like homeodomain 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PITX2 mRNA; Amphotericin B results in decreased expression of PITX2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:220,391,417...220,411,588
Ensembl chr 2:217,717,693...217,737,293
|
|
G |
Pklr |
pyruvate kinase L/R |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PKLR mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pkp1 |
plakophilin 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PKP1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:49,861,340...49,909,162
Ensembl chr13:47,309,614...47,357,465
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PLA2G2A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Plcb1 |
phospholipase C beta 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PLCB1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PMAIP1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
increases expression |
ISO |
Amphotericin B analog results in increased expression of POLG mRNA; Amphotericin B results in increased expression of POLG mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:142,792,119...142,808,933
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Polm |
DNA polymerase mu |
increases expression |
ISO |
Amphotericin B results in increased expression of POLM mRNA |
CTD |
PMID:20849824 |
|
NCBI chr14:84,921,039...84,930,649
Ensembl chr14:80,706,345...80,717,086
|
|
G |
Ppl |
periplakin |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PPL mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:10,957,388...11,003,035
Ensembl chr10:10,450,919...10,496,575
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:243,873,524...243,878,527
Ensembl chr 1:234,460,652...234,465,961
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PSAT1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Ptpn22 |
protein tyrosine phosphatase, non-receptor type 22 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of PTPN22 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:194,055,165...194,103,209
Ensembl chr 2:191,366,808...191,414,779
|
|
G |
Ptprt |
protein tyrosine phosphatase, receptor type, T |
increases expression |
ISO |
Amphotericin B analog results in increased expression of PTPRT mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:150,189,343...151,288,145
Ensembl chr 3:150,194,859...151,288,124
|
|
G |
Rad54b |
RAD54 homolog B |
increases expression |
ISO |
Amphotericin B analog results in increased expression of RAD54B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:29,829,465...29,901,967
Ensembl chr 5:25,032,066...25,104,616
|
|
G |
Ramp3 |
receptor activity modifying protein 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of RAMP3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902
|
|
G |
Rarres1 |
retinoic acid receptor responder 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RARRES1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:151,749,715...151,783,978
|
|
G |
Rasgrp1 |
RAS guanyl releasing protein 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RASGRP1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:124,624,039...124,684,079
Ensembl chr 3:104,170,013...104,230,056
|
|
G |
Rbbp5 |
RB binding protein 5, histone lysine methyltransferase complex subunit |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RBBP5 mRNA; Amphotericin B results in decreased expression of RBBP5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:46,464,389...46,494,244
Ensembl chr13:43,912,254...43,939,107
|
|
G |
Rbm47 |
RNA binding motif protein 47 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RBM47 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:42,407,226...42,545,304
Ensembl chr14:42,154,142...42,189,431
|
|
G |
Rcan2 |
regulator of calcineurin 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RCAN2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:24,456,861...24,674,234
Ensembl chr 9:16,959,480...17,174,856
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of REL mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:101,891,238...101,922,324
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Reps2 |
RALBP1 associated Eps domain containing 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of REPS2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:35,681,260...35,954,103
Ensembl chr X:32,049,399...32,317,414
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RGS2 mRNA; Amphotericin B results in decreased expression of RGS2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:58,350,063...58,352,666
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rhd |
Rh blood group, D antigen |
increases expression |
ISO |
Amphotericin B analog results in increased expression of RHD mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:147,087,479...147,121,716
Ensembl chr 5:147,087,518...147,121,715
|
|
G |
Ripor2 |
RHO family interacting cell polarization regulator 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FAM65B mRNA; Amphotericin B results in decreased expression of FAM65B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr17:40,751,771...40,975,611
Ensembl chr17:40,323,867...40,548,092
|
|
G |
Rmnd5a |
required for meiotic nuclear division 5 homolog A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RMND5A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:104,934,160...104,991,088
Ensembl chr 4:103,379,908...103,433,051
|
|
G |
Rnase4 |
ribonuclease A family member 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RNASE4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:26,786,287...26,803,634
Ensembl chr15:24,312,464...24,330,117
|
|
G |
Rnd3 |
Rho family GTPase 3 |
increases expression |
ISO |
Amphotericin B results in increased expression of RND3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:55,981,142...55,998,494
Ensembl chr 3:35,571,143...35,589,327
|
|
G |
Rora |
RAR-related orphan receptor A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RORA mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:69,301,733...70,025,931
|
|
G |
Rps8 |
ribosomal protein S8 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of RPS8 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:130,630,362...130,632,932
Ensembl chr 5:130,629,716...130,633,268
|
|
G |
Rrad |
RRAD, Ras related glycolysis inhibitor and calcium channel regulator |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RRAD mRNA |
CTD |
PMID:28534445 |
|
NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417
|
|
G |
Rsl1d1 |
ribosomal L1 domain containing 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RSL1D1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:4,424,868...4,436,753
Ensembl chr10:4,397,821...4,439,593
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
increases expression |
ISO |
Amphotericin B results in increased expression of HLA-F mRNA |
CTD |
PMID:20849824 |
|
NCBI chr20:3,407,880...3,484,130
|
|
G |
Rtn1 |
reticulon 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of RTN1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:96,499,137...96,719,340
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of RUNX3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
Sap30 |
Sin3A associated protein 30 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of SAP30 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr16:37,758,494...37,763,825
Ensembl chr16:32,747,734...32,753,112
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SCNN1A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:158,122,962...158,146,181
|
|
G |
Serpina5 |
serpin family A member 5 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SERPINA5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:123,009,224...123,028,412
Ensembl chr 6:123,023,306...123,028,407
|
|
G |
Serpinb3a |
serpin family B member 3A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SERPINB4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:23,755,690...23,766,188
Ensembl chr13:23,236,972...23,246,985
|
|
G |
Sgk3 |
serum/glucocorticoid regulated kinase family, member 3 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of SGK3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:14,128,628...14,255,099
Ensembl chr 5:9,346,040...9,415,476
|
|
G |
Siglec1 |
sialic acid binding Ig like lectin 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of SIGLEC1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:138,740,171...138,759,966
Ensembl chr 3:118,287,988...118,306,850
|
|
G |
Sik1 |
salt-inducible kinase 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of SIK1 mRNA; Amphotericin B results in increased expression of SIK1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:9,947,104...9,958,729
Ensembl chr20:9,947,396...9,958,991
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of SLC16A6 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:94,923,888...94,946,990
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc22a14 |
solute carrier family 22, member 14 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of SLC22A14 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:118,894,537...118,916,416
Ensembl chr 8:118,895,259...118,908,255
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SLC22A7 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SLC2A5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc39a7 |
solute carrier family 39 member 7 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SLC39A7 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:4,824,967...4,828,431
Ensembl chr20:4,822,012...4,826,537
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of SLC5A1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:81,778,495...81,843,084
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slc6a6 |
solute carrier family 6 member 6 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SLC6A6 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:124,195,186...124,268,880
Ensembl chr 4:124,195,218...124,268,875
|
|
G |
Slit1 |
slit guidance ligand 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of SLIT1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127
|
|
G |
Sorbs1 |
sorbin and SH3 domain containing 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SORBS1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:249,057,324...249,279,703
Ensembl chr 1:239,108,777...239,330,169
|
|
G |
Sorl1 |
sortilin related receptor 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SORL1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:51,238,713...51,401,458
Ensembl chr 8:42,341,704...42,504,513
|
|
G |
Spag8 |
sperm associated antigen 8 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SPAG8 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:57,901,681...57,903,894
Ensembl chr 5:57,901,682...57,903,894
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects expression |
EXP |
Amphotericin B affects the expression of SPP1 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Spry1 |
sprouty RTK signaling antagonist 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of SPRY1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:122,484,995...122,490,008
Ensembl chr 2:120,556,706...120,566,189
|
|
G |
Sptbn5 |
spectrin, beta, non-erythrocytic 5 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of SPTBN5 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 3:107,013,783...107,054,878
Ensembl chr 3:107,013,265...107,054,324
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SQLE mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Stc1 |
stanniocalcin 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of STC1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:50,709,439...50,720,093
Ensembl chr15:44,299,621...44,310,264
|
|
G |
Stmn4 |
stathmin 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of STMN4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr15:40,541,305...40,559,253
Ensembl chr15:40,541,357...40,559,253
|
|
G |
Tac3 |
tachykinin precursor 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TAC3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:63,562,552...63,569,170
Ensembl chr 7:63,562,552...63,569,170
|
|
G |
Tacstd2 |
tumor-associated calcium signal transducer 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TACSTD2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:96,707,951...96,709,650
|
|
G |
Taf13 |
TATA-box binding protein associated factor 13 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TAF13 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:198,893,332...198,903,994
Ensembl chr 2:196,205,243...196,215,878
|
|
G |
Tal1 |
TAL bHLH transcription factor 1, erythroid differentiation factor |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TAL1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:133,823,093...133,837,737
Ensembl chr 5:128,587,701...128,600,976
|
|
G |
Tcf20 |
transcription factor 20 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TCF20 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:115,833,523...116,009,790
Ensembl chr 7:113,954,089...114,051,839
|
|
G |
Tenm1 |
teneurin transmembrane protein 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TENM1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:126,265,968...127,155,737
Ensembl chr X:121,403,649...122,290,207
|
|
G |
Tent5a |
terminal nucleotidyltransferase 5A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of FAM46A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:95,102,349...95,109,100
Ensembl chr 8:86,225,357...86,229,045
|
|
G |
Tfdp2 |
transcription factor Dp-2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TFDP2 mRNA; Amphotericin B results in decreased expression of TFDP2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:105,640,018...105,781,026
Ensembl chr 8:96,760,504...96,896,682
|
|
G |
Tfec |
transcription factor EC |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TFEC mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:46,072,093...46,146,200
Ensembl chr 4:45,107,641...45,180,236
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TFF1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of TGFB1 protein |
CTD |
PMID:17911647 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Themis2 |
thymocyte selection associated family member 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of THEMIS2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 5:144,991,110...145,006,362
Ensembl chr 5:144,991,112...145,006,400
|
|
G |
Tmcc1 |
transmembrane and coiled-coil domain family 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TMCC1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:149,069,252...149,239,585
Ensembl chr 4:149,069,260...149,239,620
|
|
G |
Tmem140 |
transmembrane protein 140 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TMEM140 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:64,503,621...64,514,620
Ensembl chr 4:63,536,168...63,548,455
|
|
G |
Tmem151b |
transmembrane protein 151B |
increases expression |
ISO |
Amphotericin B results in increased expression of TMEM151B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:22,953,881...22,961,726
Ensembl chr 9:15,455,801...15,464,302
|
|
G |
Tmem176b |
transmembrane protein 176B |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TMEM176B mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 4:77,766,928...77,774,740
Ensembl chr 4:77,766,928...77,774,384
|
|
G |
Tmem255a |
transmembrane protein 255A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TMEM255A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:121,836,443...121,900,718
Ensembl chr X:116,970,695...117,035,008
|
|
G |
Tmem45a |
transmembrane protein 45A |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TMEM45A mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:43,713,309...43,799,526
Ensembl chr11:43,713,782...43,799,526
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Amphotericin B results in increased expression of TNF mRNA |
CTD |
PMID:20623750 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfsf4 |
TNF superfamily member 4 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TNFSF4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr13:76,256,654...76,280,133
Ensembl chr13:73,723,329...73,746,788
|
|
G |
Tox3 |
TOX high mobility group box family member 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TOX3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr19:32,820,957...32,929,776
Ensembl chr19:16,648,342...16,757,148
|
|
G |
Tp63 |
tumor protein p63 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TP63 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:88,343,647...88,554,543
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Trem1 |
triggering receptor expressed on myeloid cells 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TREM1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 9:20,259,227...20,276,879
Ensembl chr 9:12,763,819...12,779,203
|
|
G |
Trpm3 |
transient receptor potential cation channel, subfamily M, member 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TRPM3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:229,099,741...229,984,172
Ensembl chr 1:219,672,892...220,560,717
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TRPM6 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:225,559,528...225,747,106
Ensembl chr 1:216,170,038...216,320,520
|
|
G |
Trps1 |
transcriptional repressor GATA binding 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TRPS1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 7:83,806,121...84,032,609
Ensembl chr 7:81,921,601...82,141,905
|
|
G |
Tssk2 |
testis-specific serine kinase 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of TSSK2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr11:83,086,578...83,087,933
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of TXNIP mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ube2d2b |
ubiquitin-conjugating enzyme E2D 2B |
increases expression |
ISO |
Amphotericin B analog results in increased expression of UBE2D4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr14:2,060,926...2,062,400
Ensembl chr14:1,916,845...1,917,416
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
affects expression |
EXP |
Amphotericin B affects the expression of UGT1A9 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of USP2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:53,308,264...53,336,800
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Usp36 |
ubiquitin specific peptidase 36 |
increases expression |
ISO |
Amphotericin B results in increased expression of USP36 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:103,995,970...104,027,492
Ensembl chr10:103,497,349...103,528,877
|
|
G |
Vav3 |
vav guanine nucleotide exchange factor 3 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of VAV3 mRNA; Amphotericin B results in decreased expression of VAV3 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 2:199,699,861...200,042,344
Ensembl chr 2:197,011,831...197,354,321
|
|
G |
Vgll1 |
vestigial-like family member 1 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of VGLL1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:134,979,657...134,996,007
|
|
G |
Vnn1 |
vanin 1 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of VNN1 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 1:23,356,324...23,366,629
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Xpnpep2 |
X-prolyl aminopeptidase 2 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of XPNPEP2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:132,165,696...132,194,937
Ensembl chr X:127,287,979...127,317,223
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ZBTB16 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 8:57,885,886...58,073,507
Ensembl chr 8:48,994,566...49,177,011
|
|
G |
Zfp236 |
zinc finger protein 236 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ZNF236 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr18:78,251,248...78,351,037
Ensembl chr18:75,978,231...76,073,737
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
decreases expression |
ISO |
Amphotericin B analog results in decreased expression of ZFP36L2 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:10,490,032...10,494,064
|
|
G |
Zfp652 |
zinc finger protein 652 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of ZNF652 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr10:81,123,326...81,203,153
Ensembl chr10:80,649,400...80,698,674
|
|
G |
Zfx |
zinc finger protein X-linked |
decreases expression |
ISO |
Amphotericin B results in decreased expression of ZFX mRNA |
CTD |
PMID:28534445 |
|
NCBI chr X:62,798,483...62,847,068
Ensembl chr X:58,804,691...58,853,265
|
|
G |
Zmat4 |
zinc finger, matrin type 4 |
increases expression |
ISO |
Amphotericin B analog results in increased expression of ZMAT4 mRNA |
CTD |
PMID:28534445 |
|
NCBI chr16:67,969,410...68,361,377
Ensembl chr16:67,969,416...68,361,202
|
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
methylamphotericin B results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664
|
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 5:143,913,957...143,998,746
Ensembl chr 5:138,639,569...138,714,230
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
multiple interactions |
ISO |
Emetine inhibits the reaction [sodium arsenite affects the localization of AKAP9 protein] |
CTD |
PMID:19073175 |
|
NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
multiple interactions |
ISO |
Emetine inhibits the reaction [sodium arsenite affects the localization of CAPRIN1 protein] |
CTD |
PMID:19073175 |
|
NCBI chr 3:110,606,489...110,685,408
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Emetine results in increased activity of CASP3 protein |
CTD |
PMID:14502240 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Emetine results in increased activity of CASP9 protein |
CTD |
PMID:14502240 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
multiple interactions |
ISO |
Emetine inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein] |
CTD |
PMID:19073175 |
|
NCBI chr20:31,228,624...31,271,233
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Igf2bp1 |
insulin-like growth factor 2 mRNA binding protein 1 |
multiple interactions |
ISO |
IGF2BP1 protein affects the reaction [Emetine results in increased degradation of MYCN protein] |
CTD |
PMID:37246217 |
|
NCBI chr10:81,405,021...81,447,814
Ensembl chr10:80,908,076...80,951,129
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Emetine results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK1 protein] MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:15772366 PMID:26332055 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Emetine results in increased phosphorylation of and results in increased activity of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:16364386 PMID:26332055 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation decreases phosphorylation multiple interactions |
ISO |
Emetine results in increased phosphorylation of MAPK3 protein Emetine results in decreased phosphorylation of MAPK3 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15772366 PMID:26332055 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:15772366 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:15772366 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Emetine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity multiple interactions decreases expression |
ISO |
Emetine results in decreased activity of MMP2 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein] Emetine results in decreased expression of MMP2 mRNA |
CTD |
PMID:26332055 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions decreases expression |
ISO |
Emetine results in decreased activity of MMP9 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein] Emetine results in decreased expression of MMP9 mRNA |
CTD |
PMID:26332055 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mycn |
MYCN proto-oncogene, bHLH transcription factor |
multiple interactions increases degradation |
ISO |
IGF2BP1 protein affects the reaction [Emetine results in increased degradation of MYCN protein] |
CTD |
PMID:37246217 |
|
NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:35,717,764...35,723,590
|
|
G |
Nefh |
neurofilament heavy chain |
decreases degradation |
EXP |
Emetine results in decreased degradation of NEFH mRNA |
CTD |
PMID:1280263 |
|
NCBI chr14:84,044,428...84,054,413
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
decreases degradation |
EXP |
Emetine results in decreased degradation of NEFL mRNA |
CTD |
PMID:1280263 |
|
NCBI chr15:46,477,330...46,481,203
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
decreases degradation |
EXP |
Emetine results in decreased degradation of NEFM mRNA |
CTD |
PMID:1280263 |
|
NCBI chr15:46,535,857...46,541,161
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Emetine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Emetine results in increased cleavage of PARP1 protein |
CTD |
PMID:21256112 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
decreases expression |
ISO |
Emetine results in decreased expression of RECK mRNA |
CTD |
PMID:26332055 |
|
NCBI chr 5:62,898,717...62,965,274
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 2:57,539,279...57,631,291
Ensembl chr 2:55,811,322...55,901,426
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIA1 protein]; Emetine affects the reaction [TARDBP protein binds to TIAL1 protein] |
CTD |
PMID:19765185 |
|
NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases activity |
ISO |
Emetine results in decreased activity of TGFB1 protein |
CTD |
PMID:31652400 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:84,198,141...84,225,659
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr15:10,115,954...10,465,231
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tia1 |
TIA1 cytotoxic granule-associated RNA binding protein |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIA1 protein] |
CTD |
PMID:19765185 |
|
NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:118,852,837...118,880,586
|
|
G |
Tial1 |
Tia1 cytotoxic granule-associated RNA binding protein-like 1 |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIAL1 protein] |
CTD |
PMID:19765185 |
|
NCBI chr 1:192,438,794...192,475,520
Ensembl chr 1:183,009,253...183,031,637
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Emetine results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr X:125,756,107...125,803,979
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Iodoquinol inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB11 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB1A mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression multiple interactions |
ISO |
Metronidazole results in decreased expression of ABCC2 mRNA [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO |
Metronidazole results in increased expression of ABCC3 mRNA [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC3 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Metronidazole results in increased expression of ABCG8 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of ACACA protein]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ACACA mRNA |
CTD |
PMID:34979169 PMID:37211107 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of ACACB protein] |
CTD |
PMID:37211107 |
|
NCBI chr12:48,026,394...48,138,214
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acat2l1 |
acetyl-CoA acetyltransferase 2-like 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2L1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:47,803,822...47,829,012
Ensembl chr 1:47,803,813...47,829,151
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:34979169 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of AHSG protein |
CTD |
PMID:30545405 |
|
NCBI chr11:91,625,975...91,632,583
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOA protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOB protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:68,684,541...68,697,582
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Arg2 |
arginase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ARG2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arpc3 |
actin related protein 2/3 complex, subunit 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ARPC3 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:34,172,780...34,186,651
Ensembl chr12:34,172,780...34,186,651
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ASAH1 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:57,669,927...57,701,349
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP1A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP2A3 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:58,079,710...58,111,279
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5MF protein |
CTD |
PMID:30545405 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PD protein |
CTD |
PMID:30545405 |
|
NCBI chr10:101,156,673...101,161,926
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PF protein |
CTD |
PMID:30545405 |
|
NCBI chr11:37,368,045...37,375,721
Ensembl chr11:23,881,592...23,889,119
|
|
G |
B3galt5 |
Beta-1,3-galactosyltransferase 5 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of B3GALT5 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:49,053,959...49,100,398
Ensembl chr11:35,585,220...35,630,917
|
|
G |
Clca4 |
chloride channel accessory 4 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLCA4 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:236,543,975...236,565,096
Ensembl chr 2:233,883,851...233,903,089
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein] |
CTD |
PMID:35390362 |
|
NCBI chr11:95,717,172...95,718,598
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLDN7 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:55,188,670...55,190,871
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CMBL protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Cndp2 |
carnosine dipeptidase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CNDP2 protein |
CTD |
PMID:30545405 |
|
NCBI chr18:78,039,924...78,057,030
Ensembl chr18:78,039,932...78,056,922
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX5A protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:66,818,284...66,829,691
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cox6b1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6B1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:95,002,513...95,011,516
Ensembl chr 1:85,875,109...85,884,001 Ensembl chr 2:85,875,109...85,884,001 Ensembl chr 5:85,875,109...85,884,001
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX7A2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:89,597,051...89,611,032
Ensembl chr14:51,301,168...51,301,633 Ensembl chr 8:51,301,168...51,301,633
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of CSF2 protein |
CTD |
PMID:31442584 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CTSA protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:173,988,443...173,994,320
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2D2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 7:115,815,212...115,819,281
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP3A2 mRNA Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Amiodarone]; Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Tacrolimus]; Metronidazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:15855244 PMID:15869686 PMID:19299527 PMID:30545405 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA]; [Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of CYP7A1 protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:36464106 PMID:37211107 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EPCAM protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Metronidazole results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ETFA protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:64,731,192...64,787,965
Ensembl chr 8:55,835,134...55,891,969
|
|
G |
Ezr |
ezrin |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EZR protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of FASN mRNA] |
CTD |
PMID:34979169 PMID:36464106 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of GCLM protein] |
CTD |
PMID:36535435 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,115,052...34,161,329
|
|
G |
Gipc2 |
GIPC PDZ domain containing family, member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GIPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:241,030,764...241,110,236
Ensembl chr 2:241,030,770...241,110,236
|
|
G |
Gng12 |
G protein subunit gamma 12 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GNG12 protein |
CTD |
PMID:30545405 |
|
NCBI chr 4:97,340,830...97,464,422
Ensembl chr 4:96,010,952...96,134,712
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of GPBAR1 protein] |
CTD |
PMID:37211107 |
|
NCBI chr 9:83,309,895...83,312,397
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased activity of GPT protein] |
CTD |
PMID:34979169 PMID:36464106 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GPX1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTM2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 2:198,312,179...198,316,962
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Hexb |
hexosaminidase subunit beta |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of HEXB protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:30,218,608...30,238,771
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of HMOX1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HNRNPH2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:102,074,175...102,080,115
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hp |
haptoglobin |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HP protein |
CTD |
PMID:30545405 |
|
NCBI chr19:54,449,151...54,453,701
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Htr4 |
5-hydroxytryptamine receptor 4 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of HTR4 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of HTR4 mRNA |
CTD |
PMID:36535435 |
|
NCBI chr18:58,036,277...58,221,327
Ensembl chr18:55,766,725...55,949,321
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL10 mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol S results in increased expression of IL18 protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased secretion of IL18 protein] |
CTD |
PMID:35390362 PMID:38908815 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL1B mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of IL1B protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA] |
CTD |
PMID:35390362 PMID:37269894 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Metronidazole results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:44,905,362...44,910,760
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein; [Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein] |
CTD |
PMID:31442584 PMID:37269894 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAP1 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of KRT16 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:85,669,276...85,672,211
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of LEP mRNA |
CTD |
PMID:34979169 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of LYZ2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAPK3 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mlxip |
MLX interacting protein |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of MLXIP mRNA] |
CTD |
PMID:34979169 |
|
NCBI chr12:38,789,404...38,853,059
Ensembl chr12:33,128,520...33,192,374
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein] |
CTD |
PMID:35390362 PMID:37269894 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh14 |
myosin heavy chain 14 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MYH14 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:104,232,778...104,295,369
Ensembl chr 1:95,096,266...95,158,836
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFA13 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726 Ensembl chr 7:19,526,565...19,535,726
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFAB1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:186,075,933...186,091,843
Ensembl chr 1:176,644,703...176,658,099
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Metronidazole inhibits the reaction [Indomethacin results in increased activity of NOS2 protein] |
CTD |
PMID:12568917 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc2 |
NPC intracellular cholesterol transporter 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of NPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:110,128,325...110,149,245
Ensembl chr 6:104,378,644...104,418,155
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of NR0B2 protein] |
CTD |
PMID:37211107 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of NR1H4 protein] |
CTD |
PMID:37211107 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN protein] |
CTD |
PMID:35390362 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Pdxkl1 |
pyridoxal kinase like 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PDXK protein |
CTD |
PMID:30545405 |
|
NCBI chr20:10,162,934...10,192,572
Ensembl chr20:10,164,099...10,192,739
|
|
G |
Pfn1 |
profilin 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PFN1 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PGAM1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pmm2 |
phosphomannomutase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PMM2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:7,468,371...7,489,574
Ensembl chr10:6,961,709...6,983,098
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CB protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:29,681,099...29,712,835
Ensembl chr 6:23,960,998...23,992,824
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CC protein |
CTD |
PMID:30545405 |
|
NCBI chr12:40,043,822...40,061,301
Ensembl chr12:34,383,072...34,400,553
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PSMA3 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Ralb |
RAS like proto-oncogene B |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RALB protein |
CTD |
PMID:30545405 |
|
NCBI chr13:33,140,834...33,176,997
Ensembl chr13:30,588,033...30,624,202
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RAN protein |
CTD |
PMID:30545405 |
|
NCBI chr12:33,311,155...33,314,339
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA protein] |
CTD |
PMID:35390362 PMID:37269894 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rida |
reactive intermediate imine deaminase A homolog |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RIDA protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716
|
|
G |
Rpl30 |
ribosomal protein L30 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPL30 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:67,533,420...67,536,555
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr 1:65,645,991...65,651,363
|
|
G |
Rpn2 |
ribophorin II |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPN2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:166,361,955...166,409,272
Ensembl chr 3:145,941,839...145,989,543
|
|
G |
Rps23 |
ribosomal protein S23 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS23 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:22,079,339...22,080,909
Ensembl chr 2:22,079,302...22,080,918
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS27L protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:76,443,658...76,448,593
Ensembl chr 8:67,562,483...67,567,418 Ensembl chr12:67,562,483...67,567,418 Ensembl chr 2:67,562,483...67,567,418
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
affects expression |
ISO |
Metronidazole affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
affects expression |
ISO |
Metronidazole affects the expression of HLA-DRB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,548,666...4,558,258
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RT1-DMB protein |
CTD |
PMID:30545405 |
|
NCBI chr20:4,695,009...4,702,560
Ensembl chr20:4,693,103...4,700,340
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A11 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
Scarb2 |
scavenger receptor class B, member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of SCARB2 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:15,842,583...15,894,123
Ensembl chr14:15,558,236...15,609,813
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of SCD1 protein] |
CTD |
PMID:37211107 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpinb6a |
serpin family B member 6A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SERPINB6 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:30,871,468...30,989,703
Ensembl chr17:30,871,468...31,014,427
|
|
G |
Shmt2 |
serine hydroxymethyltransferase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SHMT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:65,244,247...65,249,580
Ensembl chr 7:63,358,961...63,364,236
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SLC22A7 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SLC3A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907
|
|
G |
Slc51b |
SLC51 subunit beta |
decreases expression |
ISO |
Metronidazole results in decreased expression of SLC51B mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases expression |
ISO |
Metronidazole results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SMPD2 protein |
CTD |
PMID:30545405 |
|
NCBI chr20:46,568,627...46,571,741
Ensembl chr20:44,986,231...44,989,441
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SQLE mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of SQSTM1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA]; [Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of SREBF1 protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA |
CTD |
PMID:36464106 PMID:37211107 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of SST mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of SST mRNA |
CTD |
PMID:36535435 |
|
NCBI chr11:90,461,546...90,462,823
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of SSTR2 mRNA] |
CTD |
PMID:36535435 |
|
NCBI chr10:99,163,353...99,170,519
Ensembl chr10:98,664,216...98,674,351
|
|
G |
Tars1 |
threonyl-tRNA synthetase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TARS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:62,095,978...62,114,802
Ensembl chr 2:60,367,796...60,387,717
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA] |
CTD |
PMID:37269894 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein]; TLR4 gene mutant form results in decreased susceptibility to [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] |
CTD |
PMID:35390362 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tm9sf2 |
transmembrane 9 superfamily member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TM9SF2 protein |
CTD |
PMID:30545405 |
|
NCBI chr15:105,606,082...105,660,715
Ensembl chr15:99,201,489...99,254,049
|
|
G |
Tmed10 |
transmembrane p24 trafficking protein 10 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TMED10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:110,722,887...110,757,743
Ensembl chr 6:104,991,838...105,026,753
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein; [Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of TNF protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein] |
CTD |
PMID:31442584 PMID:35390362 PMID:37269894 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TRAF6 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 protein] |
CTD |
PMID:35390362 PMID:37269894 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Tubal3 |
tubulin, alpha-like 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TUBAL3 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:66,323,733...66,332,423
Ensembl chr17:66,323,733...66,335,355
|
|
G |
Twf1 |
twinfilin actin-binding protein 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TWF1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:127,595,210...127,607,821
Ensembl chr 7:125,716,015...125,727,894
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of TXN1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txndc5 |
thioredoxin domain containing 5 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TXNDC5 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:26,495,467...26,523,608
Ensembl chr17:26,289,880...26,318,025
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRC1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:118,468,223...118,479,968
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRFS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:34,173,787...34,190,952
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRH protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:134,782,687...134,790,882
Ensembl chr 5:129,545,984...129,554,242
|
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
EXP |
Ornidazole results in decreased expression of PLAU mRNA; Ornidazole results in decreased expression of PLAU protein |
CTD |
PMID:18998460 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775
|
|
|
G |
Aadac |
arylacetamide deacetylase |
multiple interactions increases hydrolysis decreases acetylation |
ISO |
AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin] AADAC protein results in increased hydrolysis of Rifampin |
CTD |
PMID:21856291 PMID:22207054 |
|
NCBI chr 2:146,293,449...146,351,061
Ensembl chr 2:144,135,319...144,174,734
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression increases expression |
ISO |
Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein |
CTD |
PMID:15883047 PMID:17088262 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca2 |
ATP binding cassette subfamily A member 2 |
increases expression |
ISO |
Rifampin results in increased expression of ABCA2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:28,642,660...28,662,689
Ensembl chr 3:8,244,639...8,264,537
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
decreases expression |
ISO |
Rifampin results in decreased expression of ABCA8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr10:95,416,984...95,490,647
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression multiple interactions decreases activity |
ISO EXP |
Rifampin results in decreased expression of ABCB11 mRNA [Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein Rifampin results in decreased expression of ABCB11 protein tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein] Rifampin results in decreased activity of ABCB11 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein |
CTD |
PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:25886055 PMID:28437613 PMID:35544702 PMID:35835356 More...
|
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression decreases activity affects activity |
ISO EXP |
[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter] Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate Rifampin affects the activity of ABCB1 protein |
CTD |
PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 PMID:15710169 PMID:15964336 PMID:16819505 PMID:16837569 PMID:16842400 PMID:17003290 PMID:17191263 PMID:17365992 PMID:18094037 PMID:19148864 PMID:19647009 PMID:20018165 PMID:20041327 PMID:20624464 PMID:22258563 PMID:22914566 PMID:23685082 PMID:23707768 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25542144 PMID:26301745 PMID:26394120 PMID:27199754 PMID:27871908 PMID:27918128 PMID:29356861 PMID:30071242 PMID:31233785 PMID:32092453 PMID:33002526 PMID:34689256 PMID:35972551 PMID:36893891 PMID:37285043 More...
|
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
ISO |
Rifampin results in increased expression of ABCB4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 4:26,106,895...26,164,440
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Rifampin results in increased expression of ABCB6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC1 mRNA |
CTD |
PMID:17191263 PMID:35972551 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC10 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export multiple interactions increases expression |
ISO EXP |
ABCC2 protein affects the export of Rifampin [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein [Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein |
CTD |
PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 PMID:20832446 PMID:25313206 PMID:27199754 PMID:35835356 More...
|
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression increases activity |
ISO |
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA] Rifampin results in increased expression of ABCC3 mRNA Rifampin results in increased activity of ABCC3 protein |
CTD |
PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 PMID:23137910 PMID:27199754 More...
|
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC5 mRNA |
CTD |
PMID:19041851 |
|
NCBI chr11:93,975,579...94,071,659
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcf1 |
ATP binding cassette subfamily F member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCF1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,802,488...2,815,433
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein |
CTD |
PMID:12040753 PMID:17088262 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:16837569 PMID:27199754 PMID:35972551 PMID:38423481 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Rifampin results in increased expression of ABCG8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Abi3 |
ABI family, member 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of ABI3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:81,266,571...81,277,561
Ensembl chr10:80,769,822...80,780,816
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Rifampin results in increased expression of ACACA mRNA |
CTD |
PMID:27806127 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein |
CTD |
PMID:36878459 |
|
NCBI chr X:110,739,633...110,803,416
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Actr10 |
actin related protein 10 |
increases expression |
ISO |
Rifampin results in increased expression of ACTR10 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:89,446,141...89,472,350
Ensembl chr 6:89,446,093...89,473,047
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
increases expression |
ISO |
Rifampin results in increased expression of ADH1C mRNA |
CTD |
PMID:12040753 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:33412187 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adora2a |
adenosine A2a receptor |
decreases expression |
ISO |
Rifampin results in decreased expression of ADORA2A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Agap2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of AGAP2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:64,782,618...64,799,624
Ensembl chr 7:62,897,282...62,914,295
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA] Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein |
CTD |
PMID:22733800 PMID:28428138 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of AKR1B10 mRNA pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
Rifampin results in increased expression of ALAS1 mRNA |
CTD |
PMID:24259679 PMID:24552687 |
|
NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases activity multiple interactions |
ISO |
Rifampin results in increased activity of ALPL protein [Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein |
CTD |
PMID:25886055 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 5:118,818,494...118,825,531
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankrd40 |
ankyrin repeat domain 40 |
increases expression |
EXP |
Rifampin results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320 Ensembl chr10:79,282,075...79,295,320
|
|
G |
Ankrd65 |
ankyrin repeat domain 65 |
decreases expression |
ISO |
Rifampin results in decreased expression of ANKRD65 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:171,680,597...171,682,854
Ensembl chr 5:166,397,748...166,400,953
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
decreases expression |
ISO |
Rifampin results in decreased expression of ANKS1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:26,200,649...27,366,552
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apob |
apolipoprotein B |
decreases expression multiple interactions affects secretion |
ISO |
Rifampin results in decreased expression of APOB mRNA ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA] Rifampin affects the secretion of APOB protein |
CTD |
PMID:32535746 |
|
NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc3 |
apolipoprotein C3 |
decreases expression decreases secretion |
ISO |
Rifampin results in decreased expression of APOC3 mRNA Rifampin results in decreased secretion of APOC3 protein |
CTD |
PMID:32535746 |
|
NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp4 |
aquaporin 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of AQP4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Arsj |
arylsulfatase family, member J |
decreases expression |
ISO |
Rifampin results in decreased expression of ARSJ mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
EXP ISO |
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein] |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
Rifampin results in increased expression of ATF6 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr13:85,460,312...85,639,959
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions decreases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein Rifampin results in decreased expression of ATM mRNA |
CTD |
PMID:21224054 PMID:24552687 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp6v0a1 |
ATPase H+ transporting V0 subunit a1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of ATP6V0A1 protein [Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein] |
CTD |
PMID:31648047 |
|
NCBI chr10:86,436,089...86,490,185
Ensembl chr10:85,935,854...85,989,895
|
|
G |
Atp6v0d1 |
ATPase H+ transporting V0 subunit D1 |
multiple interactions |
ISO |
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:31648047 |
|
NCBI chr19:50,313,268...50,357,248
Ensembl chr19:33,403,355...33,447,450
|
|
G |
Atrx |
ATRX, chromatin remodeler |
increases expression |
ISO |
Rifampin results in increased expression of ATRX mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:74,916,548...75,062,880
Ensembl chr X:70,850,981...70,997,330
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Rifampin results in decreased expression of BAX protein |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 PMID:33629115 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of BCL2 protein [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein] |
CTD |
PMID:11958592 PMID:21419764 PMID:31629065 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of BCL2L1 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:19,618,542...19,623,306
|
|
G |
C17h9orf153 |
similar to human chromosome 9 open reading frame 153 |
decreases expression |
ISO |
Rifampin results in decreased expression of C9ORF153 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:4,975,415...4,982,400
Ensembl chr17:4,964,834...4,982,766
|
|
G |
C19h4orf51 |
similar to human chromosome 4 open reading frame 51 |
decreases expression |
ISO |
Rifampin results in decreased expression of C4ORF51 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:28,669,044...28,704,512
Ensembl chr19:28,669,059...28,704,508
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:88,550,681...88,593,454
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein] |
CTD |
PMID:26086368 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3 [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] |
CTD |
PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 PMID:26775663 PMID:31678598 PMID:35835356 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein] |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein |
CTD |
PMID:36878459 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr3 |
carbonyl reductase 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr11:46,478,295...46,486,555
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of CCL2 mRNA |
CTD |
PMID:25051504 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
EXP |
Rifampin results in decreased expression of CCL5 protein |
CTD |
PMID:25051504 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:55,022,037...55,055,857
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
Rifampin results in increased expression of CD36 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein |
CTD |
PMID:21224054 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein] |
CTD |
PMID:33412187 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein] |
CTD |
PMID:33412187 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA] |
CTD |
PMID:33412187 |
|
NCBI chr11:98,268,856...98,269,994
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Rifampin results in increased expression of CES1 protein |
CTD |
PMID:10640517 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA] |
CTD |
PMID:10640517 PMID:17003103 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions increases expression |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form] Rifampin results in increased expression of CFLAR protein |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:51,448,838...51,481,159
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Ciz1 |
CDKN1A interacting zinc finger protein 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CIZ1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:15,658,479...15,673,762
Ensembl chr 3:15,658,539...15,673,762
|
|
G |
Clk2 |
CDC-like kinase 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of CLK2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:176,868,423...176,880,412
Ensembl chr 2:174,570,653...174,588,985
|
|
G |
Cntln |
centlein |
increases expression |
ISO |
Rifampin results in increased expression of CNTLN mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:99,295,865...99,576,402
Ensembl chr 5:99,296,000...99,576,396
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
Rifampin results in increased expression of CPT1A mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CRHR1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein |
CTD |
PMID:16943303 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csnk1g1 |
casein kinase 1, gamma 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CSNK1G1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:75,334,751...75,472,339
Ensembl chr 8:66,439,864...66,572,826
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Rifampin results in increased expression of CXCL1 protein |
CTD |
PMID:25051504 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions affects expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA Rifampin affects the expression of CXCL10 protein |
CTD |
PMID:21224054 PMID:25051504 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyb5rl |
cytochrome b5 reductase-like |
increases expression |
ISO |
Rifampin results in increased expression of CYB5RL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:121,846,223...121,868,287
Ensembl chr 5:121,847,952...121,868,745
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression |
EXP ISO |
Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Rifampin results in increased activity of CYP1A1 protein Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 PMID:24999631 PMID:29162470 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO EXP |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein |
CTD |
PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 PMID:30503582 PMID:32633153 More...
|
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21224054 PMID:29162470 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO |
NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter] Rifampin results in increased activity of CYP24A1 protein |
CTD |
PMID:15630458 PMID:21127053 |
|
NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene] Rifampin results in increased expression of CYP27A1 mRNA |
CTD |
PMID:17088262 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
increases expression decreases expression |
EXP ISO |
Rifampin results in increased expression of CYP2A1 mRNA Rifampin results in increased expression of CYP2A13 mRNA Rifampin results in decreased expression of CYP2A13 mRNA |
CTD |
PMID:19118567 PMID:22258563 |
|
NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression |
ISO |
Rifampin results in increased expression of CYP2A4 mRNA |
CTD |
PMID:30503582 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases activity multiple interactions increases expression |
ISO |
Rifampin results in increased activity of CYP2B6 protein [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein |
CTD |
PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 PMID:15548381 PMID:15629111 PMID:15802389 PMID:16608920 PMID:17041008 PMID:17438109 PMID:17954527 PMID:18094037 PMID:18332078 PMID:19118567 PMID:19202563 PMID:19497361 PMID:20035023 PMID:20361990 PMID:21224054 PMID:21315811 PMID:22126990 PMID:22258563 PMID:22524704 PMID:22733800 PMID:23732298 PMID:24038852 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25835148 PMID:25929522 PMID:26196221 PMID:27871908 PMID:27917125 PMID:28289823 PMID:28887089 PMID:29356861 PMID:30071242 PMID:30503582 PMID:34689256 More...
|
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein |
CTD |
PMID:22258563 PMID:31629065 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases activity increases expression multiple interactions |
ISO |
Rifampin results in increased activity of CYP2C19 protein Rifampin results in increased expression of CYP2C29 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein Rifampin results in increased expression of and results in increased activity of CYP2C19 protein |
CTD |
PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 PMID:22126990 PMID:22310298 PMID:24552687 PMID:24830941 PMID:25835148 PMID:27917125 PMID:30503582 More...
|
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects binding multiple interactions increases expression increases activity |
ISO |
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein Rifampin results in increased activity of CYP2C8 protein |
CTD |
PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 PMID:22126990 PMID:25313206 PMID:29356861 PMID:31629065 More...
|
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases expression increases activity decreases expression |
ISO |
Rifampin results in increased expression of CYP2D6 mRNA Rifampin results in increased activity of CYP2D6 protein Rifampin results in decreased expression of CYP2D22 mRNA |
CTD |
PMID:19041851 PMID:30503582 PMID:33844597 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity decreases expression multiple interactions increases expression |
ISO EXP |
Rifampin results in increased activity of CYP2E1 protein Rifampin results in decreased expression of CYP2E1 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein] |
CTD |
PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 PMID:27919644 PMID:30503582 PMID:32633153 More...
|
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22258563 |
|
NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2J2 mRNA |
CTD |
PMID:33263786 |
|
NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects activity increases expression decreases response to substance increases activity |
EXP ISO |
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein Rifampin affects the activity of CYP3A4 protein Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] CYP3A4 protein results in decreased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:8632764 PMID:9298257 PMID:9512926 PMID:10219967 PMID:10640517 PMID:10859152 PMID:11581012 PMID:12040753 PMID:12065438 PMID:12072427 PMID:12235278 PMID:12417264 PMID:12505310 PMID:12584154 PMID:12642470 PMID:12673034 PMID:12695340 PMID:12695342 PMID:12851153 PMID:14600250 PMID:14636322 PMID:14709624 PMID:14722322 PMID:14977870 PMID:15075359 PMID:15466163 PMID:15548381 PMID:15554232 PMID:15629111 PMID:15681896 PMID:15710169 PMID:15769886 PMID:15771232 PMID:15802389 PMID:15833926 PMID:15855724 PMID:15964336 PMID:15977188 PMID:16146350 PMID:16184197 PMID:16565514 PMID:16608920 PMID:16632523 PMID:16819505 PMID:16837568 PMID:17003103 PMID:17041008 PMID:17270371 PMID:17293382 PMID:17438109 PMID:17590308 PMID:17936189 PMID:17954527 PMID:17998298 PMID:18094037 PMID:18332045 PMID:18332078 PMID:18505790 PMID:18799805 PMID:18839173 PMID:19041297 PMID:19118567 PMID:19135037 PMID:19202563 PMID:19230594 PMID:19686824 PMID:19854261 PMID:20035023 PMID:20035846 PMID:20233841 PMID:20361990 PMID:20599501 PMID:21127053 PMID:21292004 PMID:21315811 PMID:21402137 PMID:21641981 PMID:21742782 PMID:21764778 PMID:21856291 PMID:21920351 PMID:21924250 PMID:21998292 PMID:22093699 PMID:22126990 PMID:22159698 PMID:22178124 PMID:22258563 PMID:22310298 PMID:22310326 PMID:22314385 PMID:22524704 PMID:22664347 PMID:22687401 PMID:22733800 PMID:22843569 PMID:22982774 PMID:23153560 PMID:23707768 PMID:23732298 PMID:23845848 PMID:23850985 PMID:23899473 PMID:24038852 PMID:24146111 PMID:24204015 PMID:24259679 PMID:24552687 PMID:24685772 PMID:24752503 PMID:24999631 PMID:25069801 PMID:25084468 PMID:25313206 PMID:25455453 PMID:25512232 PMID:25542144 PMID:25616597 PMID:25929522 PMID:26196221 PMID:26201057 PMID:26301745 PMID:26341324 PMID:26616219 PMID:27177772 PMID:27180241 PMID:27507784 PMID:27590069 PMID:27794450 PMID:27871908 PMID:27917125 PMID:27919644 PMID:28289823 PMID:28571685 PMID:28887089 PMID:28916285 PMID:29162470 PMID:29356861 PMID:29933105 PMID:30044681 PMID:30071242 PMID:30087611 PMID:31132328 PMID:31233785 PMID:31870919 PMID:31877331 PMID:32092453 PMID:32682830 PMID:33002526 PMID:33263786 PMID:33629115 PMID:33844597 PMID:34021354 PMID:34689256 PMID:36288780 PMID:36893891 PMID:37285043 PMID:38823534 More...
|
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] |
CTD |
PMID:12370413 PMID:19041297 PMID:22159698 PMID:22310326 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
Rifampin results in increased expression of CYP3A5 mRNA |
CTD |
PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 PMID:20832446 PMID:24146111 PMID:24259679 PMID:28496040 More...
|
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein Rifampin results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 PMID:34689256 PMID:35835356 More...
|
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dcaf5 |
DDB1 and CUL4 associated factor 5 |
decreases expression |
ISO |
Rifampin results in decreased expression of DCAF5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:104,904,423...104,993,150
Ensembl chr 6:99,171,506...99,260,110
|
|
G |
Dclre1b |
DNA cross-link repair 1B |
decreases expression |
ISO |
Rifampin results in decreased expression of DCLRE1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:193,998,350...194,006,873
Ensembl chr 2:191,309,913...191,318,423
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA] Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein |
CTD |
PMID:21224054 PMID:27470132 PMID:32535746 PMID:33629115 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
multiple interactions |
ISO |
[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA |
CTD |
PMID:22101211 |
|
NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
increases expression |
ISO |
Rifampin results in increased expression of DIO1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:122,074,279...122,090,970
|
 | |